In the first quarter of 2026, Nigeria recorded 20,838 new HIV-positive cases, according to the Nigerian National Data Repository (NDR). A BusinessDay analysis estimated that administering two doses of Lenacapavir (LEN) at N58,000 per dose could have prevented these cases at a total cost of N2.4 billion. Oyebade Funmilade, an HIV prevention and treatment expert, stated, "Many of these cases may have been preventable if vaccines were available and administered." Lagos reported the highest number of cases with 2,298, requiring about N266.6 million for prevention, followed by Benue with 1,949 cases and N226 million in estimated costs. Akwa Ibom, Rivers, and Anambra recorded between 1,013 and 1,159 cases each, with prevention costs ranging from N117 million to N134 million. States like Yobe, Sokoto, and Ekiti reported fewer cases—between 100 and 129—but experts caution this may reflect poor testing and reporting rather than lower risk. The national HIV prevalence among adults aged 15–49 is now 1.3 percent, down from 2.8 percent, yet Nigeria still ranks fourth globally in HIV burden, with 1.9 million people living with the virus. Women are disproportionately affected, with a prevalence rate of 1.9 percent compared to 0.9 percent in men. The Federal Ministry of Health and Social Welfare, with support from the WHO, has begun rolling out lenacapavir as a long-acting injectable for HIV prevention.
Spending N2.4 billion to prevent 20,838 HIV infections looks like a bargain next to lifelong treatment costs, yet Nigeria is still lagging in rollout. The Federal Ministry of Health and Social Welfare's delayed deployment of lenacapavir, despite WHO support, suggests prevention remains a secondary priority. If the same money is spent reacting to infections rather than stopping them, the burden on families and the health system will only grow. This isn't about lacking solutions—it's about choosing not to act decisively when the data is already clear.
